AbbVie Resolves Lawsuit with Generic Upadacitinib Manufacturers.
PorAinvest
viernes, 12 de septiembre de 2025, 6:49 am ET1 min de lectura
ABBV--
The agreement, which includes license terms, prevents generic entry for Upadacitinib tablets until April 2037 in the United States. Pediatric exclusivity could further extend the market protection under the agreement [1]. This settlement is a strategic move for AbbVie to maintain its market share and revenue stream from Upadacitinib, a key drug in its portfolio.
The settlement comes amid strong sales performance for Upadacitinib. In the second quarter of 2025, Rinvoq (Upadacitinib) sales reached $2.03 billion, an increase of 41.8% year over year (+41.2% on an operational basis) [1]. The FDA approved Upadacitinib for treating giant cell arteritis in April, further expanding its indications [1].
While the settlement does not impact AbbVie's net sales, which are primarily generated in the United States and other developed markets, it does provide a buffer against generic competition. This allows AbbVie to continue generating revenue from Upadacitinib while potentially securing a more stable pricing environment.
Investors should monitor the ongoing legal battle between Ionis Pharmaceuticals (IONS) and Arrowhead Pharmaceuticals (ARWR), which could have broader implications for the pharmaceutical industry [2]. However, the immediate focus remains on AbbVie's strategic move to secure market protection for Upadacitinib.
AbbVie Inc. has settled a lawsuit with generic producers of Upadacitinib, a drug intended for treating rheumatoid arthritis, psoriasis, and other conditions. The settlement resolves patent infringement claims and allows generic versions of the drug to enter the market. AbbVie will receive royalties on sales of generic Upadacitinib. The settlement will not impact AbbVie's net sales, which are primarily generated in the United States and other developed markets.
AbbVie Inc. (ABBV) has reached a settlement with generic producers of Upadacitinib, a drug intended for treating rheumatoid arthritis, psoriasis, and other conditions. The settlement resolves patent infringement claims and allows generic versions of the drug to enter the market, with AbbVie receiving royalties on sales of generic Upadacitinib [1].The agreement, which includes license terms, prevents generic entry for Upadacitinib tablets until April 2037 in the United States. Pediatric exclusivity could further extend the market protection under the agreement [1]. This settlement is a strategic move for AbbVie to maintain its market share and revenue stream from Upadacitinib, a key drug in its portfolio.
The settlement comes amid strong sales performance for Upadacitinib. In the second quarter of 2025, Rinvoq (Upadacitinib) sales reached $2.03 billion, an increase of 41.8% year over year (+41.2% on an operational basis) [1]. The FDA approved Upadacitinib for treating giant cell arteritis in April, further expanding its indications [1].
While the settlement does not impact AbbVie's net sales, which are primarily generated in the United States and other developed markets, it does provide a buffer against generic competition. This allows AbbVie to continue generating revenue from Upadacitinib while potentially securing a more stable pricing environment.
Investors should monitor the ongoing legal battle between Ionis Pharmaceuticals (IONS) and Arrowhead Pharmaceuticals (ARWR), which could have broader implications for the pharmaceutical industry [2]. However, the immediate focus remains on AbbVie's strategic move to secure market protection for Upadacitinib.
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema
Comentarios
Aún no hay comentarios